You are here
San Antonio Breast Cancer Symposium
Plenary Session – December 5, 2018
The best talk I heard on Wednesday at the San Antonio Breast Cancer Symposium was the plenary lecture presented by Nicholas Navin of the UT MD Anderson Cancer Center in Houston.
The talk, “Breast Tumor Evolution and Intratumor Heterogeneity — Insights from Single Cell Genomics,” focused on scientists’ use of single cell genomics to understand how ductal carcinoma in situ (DCIS) evolves into invasive cancer.
December 4, 2018
The actual San Antonio Breast Cancer Symposium kicks off tomorrow, but there were several education sessions held on Tuesday afternoon to get us warmed up.
Tamoxifen has been used for so long to treat breast cancer that most of us assumed we knew everything that we needed to know about it—including how long women should take it. But yesterday at the San Antonio Breast Cancer Symposium we all learned something new when researchers presented results from the ATLAS trial (Adjuvant Tamoxifen: Longer Against Shorter).
Lots of medical meetings are held at this time of year, which means lots of media coverage of new breast cancer research. Whenever you hear about a new study, keep in mind that any results that are presented but not published have not passed the critical peer review process and are considered preliminary.